Lavoltidine is an orally active and irreversible histamine H2-receptor antagonist. Lavoltidine strongly suppresses gastric acid secretion and also induces hypergastrinemia.

Lavoltidine inhibits gastric atrophy, hyperplasia, and dysplasia in H felis-infected INS-GAS mice. Lavoltidine treatment for 6 months inhibits gastric tumors in H felis-infected INS-GAS mice. Lavoltidine (Loxtidine; 0.5 g/L; orally (drinking water); changed weekly; 3 months) displays partial suppression of both gastric acid secretion and progression to neoplasia [1].

76956-02-0

C19H29N5O2

359.47

Loxtidine;AH-234844

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years